The deal sees Fujifilm spreading its revenue sources by investing in biotech firms involved in regenerative pharmaceuticals and medicine. The fate of its acquisition of Xerox is still uncertain as it faces strong headwinds from activist investors Carl Icahn and Darwin Deason. In efforts aimed at boosting its healthcare business, Fujifilm Holdings said it would…